A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer

A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer

Objectives: We aim to determine the feasibility, safety, maximally tolerated dose (MTD), recommended dose and potential anti-tumor activity of intrathecal pemetrexed (IP).Materials and Methods: Lung adenocarcinoma patients with recurrent or progressive leptomeningeal metastases (LM) after intratheca...

Full description

Bibliographic Details
Main Authors: Zhenyu Pan, Guozi Yang, Jiuwei Cui, Wei Li, Yu Li, Pengxiang Gao, Tongchao Jiang, Yanan Sun, Lihua Dong, Yuanyuan Song, Gang Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-08-01
Series:Frontiers in Oncology
Subjects:
leptomeningeal metastases
non-small cell lung cancer
intrathecal chemotherapy
pemetrexed
refractory
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00838/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00838/full

Similar Items